These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 7779413

  • 1. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
    Olive PL.
    Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
    [Abstract] [Full Text] [Related]

  • 2. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
    Olive PL.
    Br J Cancer; 1995 Mar; 71(3):529-36. PubMed ID: 7880735
    [Abstract] [Full Text] [Related]

  • 3. Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice.
    Olive PL, Vikse CM, Banath JP.
    Cancer Res; 1996 Oct 01; 56(19):4460-3. PubMed ID: 8813141
    [Abstract] [Full Text] [Related]

  • 4. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.
    Olive PL.
    Br J Cancer; 1995 Mar 01; 71(3):537-42. PubMed ID: 7880736
    [Abstract] [Full Text] [Related]

  • 5. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
    Keohane A, Godden J, Stratford IJ, Adams GE.
    Br J Cancer; 1990 May 01; 61(5):722-6. PubMed ID: 2110815
    [Abstract] [Full Text] [Related]

  • 6. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG, van Zijl PL, Brown JM.
    Br J Cancer; 1996 Apr 01; 73(8):952-60. PubMed ID: 8611431
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ.
    Br J Cancer; 1997 Apr 01; 76(10):1338-47. PubMed ID: 9374381
    [Abstract] [Full Text] [Related]

  • 8. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
    Hwang JT, Greenberg MM, Fuchs T, Gates KS.
    Biochemistry; 1999 Oct 26; 38(43):14248-55. PubMed ID: 10571998
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of DNA damage in mammalian cells upon bioreduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131.
    Jenner TJ, Sapora O, O'Neill P, Fielden EM.
    Biochem Pharmacol; 1988 Oct 15; 37(20):3837-42. PubMed ID: 3190731
    [Abstract] [Full Text] [Related]

  • 10. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P, Stratford IJ.
    Cancer Metastasis Rev; 1993 Jun 15; 12(2):73-82. PubMed ID: 8375022
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of oncogenicity for bioreductive drugs.
    Hei TK, Piao CQ, He ZY, Hall EJ.
    Int J Radiat Oncol Biol Phys; 1992 Jun 15; 22(4):747-50. PubMed ID: 1544847
    [Abstract] [Full Text] [Related]

  • 12. Bioreductive drugs and the selective induction of tumour hypoxia.
    Bremner JC, Stratford IJ, Bowler J, Adams GE.
    Br J Cancer; 1990 May 15; 61(5):717-21. PubMed ID: 2110814
    [Abstract] [Full Text] [Related]

  • 13. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ, Moini M, Giuliano J, Westra WH.
    Ann Acad Med Singap; 1996 May 15; 25(3):397-404. PubMed ID: 8876907
    [Abstract] [Full Text] [Related]

  • 14. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M, Stevens G.
    Melanoma Res; 1998 Dec 15; 8(6):510-5. PubMed ID: 9918413
    [Abstract] [Full Text] [Related]

  • 15. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG, Menke DR, Dorie MJ, Brown JM.
    Cancer Res; 1997 Jul 15; 57(14):2922-8. PubMed ID: 9230202
    [Abstract] [Full Text] [Related]

  • 16. Reduction of tumor hypoxia and inhibition of DNA repair by nicotinamide after irradiation of SCCVII murine tumors and normal tissues.
    Zheng H, Olive PL.
    Cancer Res; 1996 Jun 15; 56(12):2801-8. PubMed ID: 8665517
    [Abstract] [Full Text] [Related]

  • 17. The in situ tumour response to combinations of cyclophosphamide and tirapazamine.
    Siemann DW.
    Br J Cancer Suppl; 1996 Jul 15; 27():S65-9. PubMed ID: 8763849
    [Abstract] [Full Text] [Related]

  • 18. Assessment of the repair and damage of DNA induced by parent and reduced RSU-1069, a 2-nitroimidazole-aziridine.
    O'Neill P, Cunniffe SM.
    Int J Radiat Oncol Biol Phys; 1989 Apr 15; 16(4):963-6. PubMed ID: 2649467
    [Abstract] [Full Text] [Related]

  • 19. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM, Melo T, Misra V.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):755-62. PubMed ID: 9845091
    [Abstract] [Full Text] [Related]

  • 20. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Takahashi M, Abe M.
    Br J Cancer Suppl; 1996 Jul 01; 27():S61-4. PubMed ID: 8763848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.